Xcout IntelenGene Therapeutics Inc. competitors & alternatives
The 12 closest competitors and alternatives to enGene Therapeutics Inc. among biotech companies — ranked by similarity to what enGene Therapeutics Inc. actually does, not by market-cap band.
Subscribe to see enGene Therapeutics Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About enGene Therapeutics Inc.
Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.
enGene Therapeutics Inc. at a glance
enGene Therapeutics Inc. is a biotech company headquartered in Montreal, Canada. It is publicly listed (ENGN) with a market capitalisation of $115.9M. Xcout tracks 19 named people at enGene Therapeutics Inc., including Ronald H. W. Cooper (President, Chief Executive Officer & Director).
enGene Therapeutics Inc. leadership
- Ronald H. W. CooperPresident, Chief Executive Officer & Director
- Joan ConnollyChief Technology Officer
- William J. GrossmanInterim Chief Medical Officer & Director
- Amy PottChief Global Commercialization Officer
- Jill BuckChief Development Officer
- Matthew BoydChief Regulatory Officer
13 more named people on record for enGene Therapeutics Inc., with roles, board committees and tenure — see the full roster →
Top 12 enGene Therapeutics Inc. competitors
Ranked by semantic similarity — how close each company is to enGene Therapeutics Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
EdiGene is a clinical-stage biotechnology company founded in 2015 that focuses on translating gene-editing technologies into therapeutic products. Headquartered in Beijing, China, the company also operates research and office facilities in locations such as Shanghai, Guangzhou, and the United States.
Similar biotech company
Genprex, Inc. is a biotechnology firm specializing in gene therapy, with its primary focus on advancing treatments through clinical stages. Their mission revolves around developing innovative therapies for patients battling cancer and diabetes. Leading their product pipeline is REQORSA (GPX-001), a flagship gene therapy candidate specifically designed to target both non-small cell lung cancer and small cell lung cancer. In addition, Genprex is progressing GPX-002, another gene therapy at the preclinical stage, intended for the management of diabetes. The company was established in 2009 and operates from its corporate headquarters located in Austin, Texas.
Biotechnology
Laguna Pharmaceuticals is a biotechnology company developing precision microbial immunotherapy platforms to treat various cancers, including high-risk leukemias and soft-tissue sarcomas. The company utilizes engineered, highly attenuated microbial vectors to activate and expand innate T cells directly within the body, aiming to overcome immune evasion by tumors.
Similar biotech company
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
Similar biotech company
Elicera Therapeutics is a clinical-stage immuno-oncology company that develops genetically engineered cell and gene therapies, including CAR T-cell therapies and oncolytic viruses, to treat various types of cancer. The company utilizes its proprietary iTANK technology platform to enhance the immune system's ability to target and attack solid tumors.
Similar biotech company
AnGes, Inc., a biopharmaceutical firm headquartered in Ibaraki, Japan, and established in 1999, focuses on pioneering the research and development of gene-based medical solutions. Its primary therapeutic asset is Hepatocyte Growth Factor (HGF) Plasmid, an innovative gene therapy designed to address critical limb ischemia, a severe circulatory condition impacting the legs. The company's diverse pipeline also includes NF-kB Decoy Oligonucleotide, a nucleic acid medicine formulated to suppress inflammation for various ailments, including low back pain. Furthermore, AnGes is actively developing treatments for atopic dermatitis and disc degeneration, as well as specialized medical devices aimed at preventing vascular restenosis. Their development endeavors also extend to therapeutic vaccines for cervical intraepithelial neoplasia, a precursor to cervical cancer, and, through a research partnership with Osaka University, DNA vaccines targeting hypertension. AnGes fosters strategic alliances to expand its global reach and product commercialization. These collaborations include BioMarin Pharmaceutical Inc. for the Japanese market distribution of Naglazyme, a drug for mucopolysaccharidosis VI; and Mitsubishi Tanabe Pharma Corporation, which handles the marketing of HGF Plasmid for peripheral arterial disease in both the United States and Japan. Other key partners are SHIONOGI & CO., LTD. for the commercialization of topical NF-kB decoy oligonucleotide drugs for dermatological conditions, and Vical, Inc. for the development and marketing of Allovectin, a cancer treatment. Additionally, AnGes has joined forces with Osaka University to develop a coronavirus vaccine, and with Brickell Biotech, Inc. for an investigational plasmid DNA vaccine intended to prevent coronavirus across the U.S., South America, and other territories. The company, previously known as AnGes MG, Inc., officially rebranded to AnGes, Inc. in July 2017.
Biotechnology
Canary Cure Therapeutics is a privately held biopharmaceutical company headquartered in Burlington, Canada. It focuses on developing novel gene and RNA therapies to address various medical needs. The company operates with a small team and maintains its primary operations in Ontario.
Similar biotech company
Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their development pipeline is UCART19, an allogeneic chimeric antigen receptor (CAR) T-cell therapy. This candidate is being developed, manufactured, and prepared for market release to address relapsed/refractory (R/R) CD19-positive B-cell acute lymphoblastic leukemia (ALL) in both children and adults. The company's portfolio also encompasses ALLO-501, an anti-CD19 allogeneic CAR T-cell candidate currently in Phase I clinical trials for R/R non-Hodgkin lymphoma. A related therapeutic, ALLO-501A, is progressing through Phase I/II studies, targeting R/R large B-cell lymphoma or transformed follicular lymphoma. Furthermore, Allogene is advancing several other promising candidates: ALLO-715, an allogeneic CAR T-cell therapy in Phase I for R/R multiple myeloma; ALLO-605, another allogeneic CAR T-cell designed for multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody. Their investigational therapies also include those targeting CD70 for renal cell cancer, ALLO-819 (an allogeneic CAR T-cell treatment) for acute myeloid leukemia, and DLL3 for small cell lung cancer and other aggressive neuroendocrine tumors. Allogene maintains a robust network of strategic alliances, which includes licensing and collaboration agreements with organizations such as Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. They also hold a clinical trial collaboration with SpringWorks Therapeutics, Inc. Additionally, a strategic partnership with The University of Texas MD Anderson Cancer Center supports the preclinical and clinical evaluation of their allogeneic CAR T-cell product pipeline. Founded in 2017, the company's corporate headquarters are located in South San Francisco, California.
Similar biotech company
ArsenalBio is a biotechnology company developing programmable cell therapies, particularly engineered T-cell therapies, for cancer treatment. It serves biopharmaceutical and healthcare markets by using synthetic biology and genomic engineering to create more effective, controllable immune-cell medicines.
Biotechnology
DCx Biotherapeutics is a Canadian preclinical-stage biotechnology company developing precision oncology therapeutics and precision drug conjugates to target genetically defined cancers. The company focuses on addressing root drivers and key cellular interdependencies of cancer lesions.
Similar biotech company
Circio Holding ASA is a biotechnology company that develops novel circular RNA and immunotherapy medicines, utilizing its proprietary circVec platform to enhance gene therapy for genetic diseases. It serves the biopharmaceutical sector and patients with genetic disorders by advancing clinical programs and engaging in research collaborations.
Biotechnology
OncoSenX, Inc. is a late-stage preclinical biotechnology company headquartered in Seattle, Washington. The firm specializes in developing targeted cancer therapeutics and novel drug delivery pipelines. Its oncology technology works in coordination with parent company Entos's research platforms to advance precision gene therapies.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of enGene Therapeutics Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for enGene Therapeutics Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →